FIGURE 1.

MZT2A overexpression and association with poor NSCLC prognosis. A, Differential MZT2A expression in NSCLCs using TCGA data (i) and GEPIA data (ii). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. B, Kaplan‐Meier survival analysis. High MZT2A expression is associated with poor NSCLC prognosis. C, Immunohistochemistry. MZT2A expression in our cohort of 132 NSCLC cases was analyzed. i, Weak MZT2A expression in normal bronchial epithelium. ii, Strong staining of MZT2A in mitosis‐stage cells. iii, iv, MZT2A expression in LUSC and adenocarcinoma cells. D, Western blot. NSCLC cell lines and HBE cells were grown and harvested for western blot analysis. The data showed that MZT2A expression was highest in H292 cells and lowest expressed in H460 cells. The graph is the quantified data for the western blots. E, Immunofluorescence. NSCLC A549 and H1299 cells were grown and immunostained with an MZT2A antibody. The data show that MZT2A was mainly localized in the cytoplasm with some staining in the nuclei